ADVERTISEMENT
Torrent Pharma Q3 Results : PL Capital Recommends 'Accumulate' On The Stock, Hikes Target Price — Here's Why
Torrent Pharma continues to explore inorganic opportunities which will be key for stock performance, says the brokerage.
27 Jan 2025, 04:38 PM IST 
Torrent Pharmaceuticals Ltd.’s Q3 FY25 Ebitda missed estimates however PAT was largely in line. (Source: freepik)
Torrent Pharma's chronic division achieved a 14% growth in market share, driven by a strong 16% increase in the Cardiac portfolio. The company gained market share in focus therapies such as Cardiac, Diabetes and Gastro.
